-
Treprostinil Phase 1 Clinical Trial Completed
Treprostinil — a vasodilator — was approved by the U.S. Food and Drug Administration (FDA) in 2002 for the treatment of pulmonary arterial hypertension. The drug is commercially available as Tyvaso, Orenitram, and Remodulin.
A Phase 1 clinical trial (NCT03464864) found that treprostinil can be safely delivered at varying doses using Technosphere, a novel inhalation device, MannKind, the device’s developer, announced.
Read more about this clinical trial here: Treprostinil Delivered Using Technosphere Portable Inhaler Seen as Safe in Early Clinical Trial
Have you heard of Treprostinil or any of its commercial names? What do you think of this trial’s findings?
-
0 Replies
Sorry, there were no replies found.
Log in to reply.